Redeye is favorable to the expansion of the distribution network for Switzerland and Lichtenstein by...
Kommande fas IIb-studie Guard meddelade på måndagen att bolaget, efter återkoppling från FDA, planer...
Redeye updates its estimates before TECO’s Q4 report, where we expect that deals have been pushed to...
Q4'23 results due 2 February 23e EBITDA cut 1.4% and down 11.
Redeye endorses CLS’ market approval for its TRANBERG portfolio in Singapore.
Aptahem genomför mellan den 15-29 januari år 2024 en företrädesemission om 34,6 MSEK.
Redeye is surprised that I-Tech's CEO, Philip Chaabane has decided to step down from his position fo...
Redeye comments on Thomson Reuters' increased public offer of SEK50 per share, which the independent...
Redeye expects improved numbers in Q4 relative to soft Q2-Q3 due to seasonality and improved underly...
Redeye comments on Arise’s production figure for the fourth quarter, which was released on Friday ev...
Eevia Health Plc (”Eevia” or the “Company”) announced on Friday, January 12th, that the Company has ...
Redeye comments on the announcement that Oskar Mühlbach will leave as CEO and that Raketech's founde...
Redeye comments on Avalara’s SEK45 per share offer that arrived this morning.
We comment on the termination in this note. Due to the early stage of the program, it does not influ...
Redeye comments on the business update by CEO Pia Renaudin after the initial 100 days at Scibase.
Biosergen will conduct a new phase 1b study in patients with invasive fungal infections with its dru...
Redeye updates its estimates following Fluoguide presenting its strategic update.
Ska omsätta 450 mkr år 2027 SaveLend group har annonserat nya finansiella mål som sträcker sig till ...
Redeye comments on today's news that Thomson Reuters is offering SEK40 per share for Pagero.
Redeye comments on yesterday’s news where Tessin has secured short-term funding by issuing a convert...
